Drug-labels.com

Apo-Mirabegron: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
25 mg, 50 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Apo-Mirabegron

ABOUT THIS MEDICATION

What the medication is used for:

APO-MIRABEGRON treats the symptoms of an overactive bladder such as:

  • suddenly needing to empty your bladder (called urgency)
  • having to empty your bladder more than usual (called urinary frequency)
  • not being able to control when you empty your bladder (called urgency incontinence)

What it does:

APO-MIRABEGRON contains mirabegron. It works by relaxing the bladder smooth muscle, thereby reducing the symptoms of an overactive bladder.

When it should not be used:

  • you have very high uncontrolled blood pressure
  • if you are allergic to mirabegron or any of the ingredients in APO-MIRABEGRON
  • women who are pregnant or breastfeeding

What the medicinal ingredient is:

Mirabegron

What the nonmedicinal ingredients are:

Ascorbic acid, D&C yellow #10 aluminum lake, FD&C red #40 aluminum lake (25 mg), hydroxypropyl cellulose, hydroxypropyl methylcellulose, indigotine aluminum lake, magnesium stearate, polyethylene glycol, polyethylene oxide, sunset yellow aluminum lake, and titanium dioxide.

What dosage forms it comes in:

Extended-release tablets, 25 mg, 50 mg

WARNING AND PRECAUTION

BEFORE you use APO-MIRABEGRON talk to your doctor or pharmacist if:

  • you have problems emptying your bladder or if you have weak urine stream
  • you are pregnant or trying to become pregnant
  • you are breastfeeding or planning to breastfeed
  • you have severe liver problems
  • you have severe kidney problems
  • you have an eye problem called Glaucoma
  • you have high blood pressure or a history of high blood pressure
  • you have any heart disorder, including an irregular heartbeat, an abnormal electrical signal called “prolongation of the QT interval” or a known history of QT interval prolongation
  • you have a history of ischemic heart disease or a heart rate that is higher than normal

APO-MIRABEGRON should not be given to patients under 18 years of age.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. APO-MIRABEGRON may affect the way other medicines work, and other medicines may affect how APO-MIRABEGRON works. You may need to change the dosage or stop taking one of the medicines.

APO-MIRABEGRON may interact with the following medications:

  • Propafenone, or Flecainide, drugs used to treat irregular heartbeats
  • Digoxin
  • Drugs known to increase the heartbeat or elevate blood pressure
  • Drugs known to prolong the QT/QTc interval and/or cause torsade de pointes

PROPER USE OF THIS MEDICATION

Usual starting dose:

25 mg once daily with or without food. The tablet should be swallowed whole with a glass of water. Do not crush or chew the tablet. Based upon your response and tolerability, your doctor may increase your dose to 50 mg once daily. The maximum dose for APO-MIRABEGRON is 50 mg once daily.

Overdose:

If you think you, or a person you are caring for, have taken too much APO-MIRABEGRON, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you forget to take your medicine, then take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose. If you miss several doses, tell your doctor and follow the advice given to you.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with all medications, APO-MIRABEGRON can cause side effects. The possible common side effects are as follows:

  • Increased blood pressure
  • Cold symptoms (Nasopharyngitis)
  • Urinary tract infection
  • Constipation
  • Diarrhea
  • Dizziness
  • Headache
  • Nausea
  • Itching

SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Symptom / effectTalk to your healthcare professionalStop taking drug and get immediate medical help
Only if severeIn all cases
UncommonRash / Urticaria (hives)✓
Urinary Retention (the inability to empty your bladder)✓
Atrial fibrillation (rapid and irregular heart beat)✓
Cerebrova scular accident (stroke)✓
RareAngioedem a (swelling of the face or tongue, difficulty breathing)✓

This is not a complete list of side effects. For any unexpected effects while taking APO-MIRABEGRON, contact your doctor or pharmacist.

HOW TO STORE IT

Keep out of the reach and sight of children.

Store at room temperature 15°C to 30°C. Protect from moisture.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about APO-MIRABEGRON:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website (http://www.apotex.ca/products), or by calling 1-800-667-4708.

Last revised: JAN 30, 2026

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02564963

Revision date stated in the text: January 30, 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Apo-Mirabegron

Rx or OTC
Prescription (Rx)?
DIN 02564963, 02564971
Schedule(s) PRESCRIPTION
Active ingredient(s) Mirabegron
Dosage form(s) Tablet (Extended-Release)
Route(s) of administration Oral
Drug class (WHO ATC)
  1. G Genito urinary system and sex hormones
    1. G04 Urologicals
      1. G04B Urologicals
        1. G04BD Drugs for urinary frequency and incontinence
          1. G04BD12 Mirabegron
Company APOTEX INC
Current status Marketed
Current status date April 1, 2026
Strengths and forms
DIN Strength Dosage form(s) Current status
02564963 25 MG Tablet (Extended-Release) Marketed April 1, 2026
02564971 50 MG Tablet (Extended-Release) Marketed April 1, 2026

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.